ACG Meeting Bonus Sessions 2021

Separate Purchase Required – Must be registered for the Annual Scientific Meeting to purchase access to these sessions.

(Formerly Breakfast Sessions)

• GI Cancer Disparities: Challenges and Solutions
  Folasade P. May, MD, PhD, MPhil
  Describe the impact of disparities in GI cancers and identify approaches to increase screening rates and access to care in populations most at-risk.
• Liver Transplant Continuum Among Marginalized Minorities: Identifying and Overcoming Obstacles
  Julius M. Wilder, MD, PhD
  Recognize the barriers to liver transplantation that marginalized populations often encounter and define strategies to achieve equity in transplantation.
• IBD Disparities in Minority Communities: Bridging the Gap
  Adjoa N. Anyane-Teboa, MD, MPH
  Identify racial and socioeconomic status inequities to accessing and utilizing IBD-related care.

• The Trailer: Endoscopic Activity — Describe What You See
  Anita Afzali, MD, MPH, FACG
  Assess various levels of endoscopic activity and commonly used endoscopic scores in IBD.
• The Watchful Eye: Colorectal Cancer and Dysplasia Surveillance
  David T. Rubin, MD, FACG
  Describe endoscopic dysplastic surveillance in IBD and identify visible, discreet, and resectable lesions.
• After the Final Cut: Endoscopic Post-Surgical Anatomy in Crohn’s Disease
  Miguel D. Regueiro, MD, FACG
  Differentiate various forms of post-surgical anatomy and recognize surgical complications during endoscopy.

• Evaluation of NAFLD/NASH Initial Work-Up and Current Treatment Options
  Manal F. Abdelmalek, MD, MPH, FACG
  Describe an evidence-based approach to the initial work-up for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, along with current treatment options, including lifestyle modifications and weight loss.
• Future Medical Treatments for NAFLD/NASH
  Naim Alkhouri, MD
  Summarize evolving and future strategies for NASH treatment, including clinical trial data and implications for clinical practice.
• Bariatric Endoscopic and Surgical Approaches to Weight Loss for Fatty Liver Disease: What to Use When
  Pichamol Jirapinyo, MD, MPH, and Julie K. Heimbach, MD, FACS
  Discuss and compare the role of current and evolving techniques for bariatric endoscopy vs. bariatric surgery, and their potential role in the management of non-alcoholic fatty liver disease.

• The Cutting Edge of Esophageal Strictures
  Jason B. Samarasena, MD, FACG
  Discuss esophageal stricture types (benign, malignant, refractory) as well as the optimal endoscopic approach for each (dilation, incisional therapy, stent, newer techniques).
• Malignant Gastric Outlet Obstruction: Duodenal Stent, LAMS, or Surgery?
  Richard A. Kozarek, MD, FACG
  Compare outcomes for managing GOO with duodenal stent, EUS-guided gastroenterostomy with LAMS, and surgery; and discuss selection of optimal approach and endoscopic techniques.
• From Volvulus to Colonic Strictures: Endoscopy Versus Surgery
  Rebecca A. Burbridge, MD
  Outline best approaches for treating colonic volvulus and benign and malignant colonic strictures, including dilation and stent versus surgery.

• Small Intestinal Bacterial Overgrowth: What’s New?
  Baharak Moshiree, MD, MSc
  Describe the most up-to-date diagnostic and treatment approaches for SIBO.
• Exocrine Pancreatic Insufficiency: Optimizing Your Practice
  Jodie A. Barkin, MD
  Recognize symptoms of and treatment approaches for exocrine pancreatic insufficiency and identify consequences if left untreated.
• What’s on the Horizon for Celiac Disease and Non-Celiac Gluten Sensitivity: Serologies, Dietary, and Non-Dietary Therapies
  Benjamin Lebwohl, MD, MS
  Explore new developments in serologic testing, dietary modification, and pharmacologic therapies for celiac disease and non-celiac gluten sensitivity.

• EoE Diagnosis and Management in Adult vs Pediatric Populations
  Amiko M. Uchida, MD, and Jacob Robson, MD
  Discuss special considerations needed for evaluating and treating EoE in children compared to adults.
• EoE Treatment: Predicting Success or Failure
  Joy W. Chang, MD
  Recognize how specific endoscopic or clinical characteristics predict treatment responses and failures in patients with EoE.
• Future of EoE: Do We Know What We Don’t Know?
  Ikuo Hirano, MD, FACG
  Review controversial aspects to treatment and describe how physician-patient shared decision making can aid in management of difficult patients with EoE.

• Liver Diseases and Pregnancy
  Nancy S. Reau, MD, FACG
  Discuss the management of chronic liver diseases in the context of pregnancy, and review evidence-based guidance in the evaluation and treatment of the pregnant patient with intrahepatic cholestasis, acute fatty liver, and HELLP syndrome.
• Fibrosure, Fibroscan, and Beyond: Using Non-Invasive Liver Fibrosis Tests in Clinical Practice
  Joseph K. Lim, MD, FACG
  Review current guidelines on non-invasive liver fibrosis tests, such as serum fibrosis assays and imaging-based elastography, in clinical practice for patients with viral hepatitis and other chronic liver disorders.
• The Epidemic of Alcoholic Hepatitis: STOPAH the Steroids or Not? Transplant or Not?
  Ashwani K. Singal, MD, MS, FACG
  Summarize new guideline recommendations in the evaluation, diagnosis, and management of severe acute alcoholic hepatitis, including the role of corticosteroids and liver transplantation.

• Medical Management of Obesity
  Shelby A. Sullivan, MD, FACG
  Discuss different options for medical management of obesity including diet, exercise, and medications.
• Primary Endoscopic Bariatric and Metabolic Therapies
  Christopher C. Thompson, MD, MSc, FACG
  Describe when to offer primary endoscopic treatment for obesity and explore current endoscopic options along with their safety and efficacy outcomes.
• Endoscopic Treatment of Weight Regain Following Bariatric Surgery
  Pichamol Jirapinyo, MD, MPH
  Outline the endoscopic approach to treating weight regain following Roux-en-Y gastric bypass and sleeve gastrectomy.

• Emerging Concepts in the Evaluation and Management of Hepatitis A and E
  Mitchell L. Shiffman, MD, FACG
  Summarize the changing epidemiology, natural history, diagnosis, and management of acute hepatitis A and E infections.
• Hepatitis B Management: Challenges and Controversies
  Stanley M. Cohen, MD, FACG
  Discuss evidence-based approaches to challenging issues in hepatitis B management including the care of chronic HBV in pregnancy, and the evaluation, prevention, and management of HBV reactivation in patients undergoing immunosuppressive drug therapy.
• Hepatitis C Treatment Issues: Elimination, DAA Failures, Special Populations, Reactivation
  Kimberly A. Brown, MD
  Review evidence-based guidelines addressing current challenges and controversies in HCV therapy, including HCV elimination, treatment of DAA failures and special populations, and the association between DAAs and both HCC and HBV reactivation.

• Motility Disorders of the Anorectum
  Lavanya Viswanathan MD, MS
  Identify when to order, how to interpret, and how to optimize treatments of various anorectal disorders using anorectal manometry.
• Office Management of Hemorrhoids and Fissures
  Waqar A. Qureshi, MD, FACG
  Explain the technique of a well-performed rectal exam, as well as medical and non-medical treatments for hemorrhoids and anal fissures, and the complications of anal fissures and hemorrhoid-based disease.
• Pruritus and Proctalgia Management
  Satish S. C. Rao, MD, PhD, FACG
  Describe the pathophysiology of and differences between pruritis ani and proctalgia fugax, and how to optimize treatment of each.

• Pin-Pointing Therapeutic Targets in Ulcerative Colitis
  Edith Y. Ho, MD, MS, FACG
  Incorporate updated recommendations for assessing UC disease activity.
• Zooming in on Therapeutic Targets in Crohn’s Disease
  Bruce E. Sands, MD, MS, FACG
  Summarize invasive and non-invasive strategies for achieving therapeutic goals in Crohn’s disease.
• Locking in on Perianal Disease IBD Targets
  David A. Schwartz, MD, FACG
  Formulate treat-to-target strategies in managing perianal Crohn’s disease.

• Obstructive Symptoms: How Best to Sort Out Dysphagia and Regurgitation
  C. Prakash Gyawali, MD, MRCP, FACG
  Explain best approaches to obstructive symptoms with and without concurrent reflux symptoms.
• Typical and Refractory Reflux Symptoms: Making the Most of Our Diagnostic Toolbox
  Amit Patel, MD
  Compare and contrast different approaches to the evaluation of reflux.
• Extra-Esophageal and Atypical Symptoms: How We Can Do Better
  Charlene Prather, MD, MPH
  Discuss current limitations in diagnosing extra-esophageal reflux (cough, LPR), and how improved patient evaluation can lead to improved management.

• What’s New in BE Screening and Surveillance
  Prateek Sharma, MD, FACG
  Review pearls of screening and surveillance in Barrett’s esophagus.
• What’s New in BE Ablation/Prevention
  Sachin B. Wani, MD
  Discuss new ablation protocols and data for prevention in Barrett’s esophagus.
• Managing Difficult and Refractory BE – A Case-Based Discussion
  Christine Y. Hachem, MD, FACG
  Identify management strategies for difficult or refractory Barrett’s esophagus.

• Telemedicine in GI – A Revolutionary Practice Platform in the Post-COVID-19 World
  Eric D. Shah, MD, MBA, FACG
  Outline ways to incorporate telemedicine into your daily clinical practice in the post-COVID-19 world.
• Building Your Brand: Using Social Media to Improve Your Practice
  Amy S. Oxentenko, MD, FACG
  Recognize how to maximize your social media experience while avoiding potential pitfalls.
• Incorporate Emerging Technologies and AI Into Your Daily Practice
  Seth A. Gross, MD, FACG
  Explore the new frontiers of cutting-edge technology and the use of artificial intelligence in GI practice.

• Evolving Management of Portal Hypertension: Beyond Non-Selective Beta Blockers
  Guadalupe Garcia-Tsao, MD, FACG
  Discuss emerging evidence to guide clinical decision-making in the management of cirrhotic portal hypertension, using statins, microbiome, DOACs, albumin, and TIPS.
• New Approaches to Diagnosis and Management of DILI
  Haripriya Maddur, MD
  Review evidence-based guidance on the evaluation and management of drug-induced liver injury including immune checkpoint inhibitor-associated hepatitis.
• Evidence-Based Approach to Liver Masses and the Role of LI-RADS
  Ayse Aytaman, MD, FACG
  Outline current guideline recommendations in the evaluation, diagnosis, and management of patients with liver lesions, and describe the utilization of LI-RADS, a standardized radiologic classification system for liver lesions.